Objective To investigate the clinical value of oxaliplatin combined with capecitabine treating advanced gastric cancer.Methods Sixty-six cases with advanced gastric cancer at first affiliated hospital of Xi'an medical university were selected and randomly divided into the observation group (33 cases) and the control group (33 cases).Patients in observation group were treated by oxaliplatin 130 mg/m2 plus capecitabine 2 500 mg/(m2 · d) chemotherapy.Patients in control group were treated by cisplatin 20 mg/m2combined with 5-fluorouracil 2 400 mg/m2,leucovorin 200 mg/m2 chemotherapy.The efficacy,quality of life and adverse drug reactions of two groups were compared.Results The effective rate of observation group was 54.5％ (18/33),which was significantly higher than that of control group [33.3％ (11/33)] (P ＜ 0.05).The quality of life score of two groups after treatment were higher than before treatment ; there were significant differences (P ＜ 0.05) [observation group:(88 ± 8) scores vs (65 ± 7) scores ; control group:(79 ± 9) scores vs (66 ± 7) scores].The quality of life score of observation group after treatment was significantly higher than that of control group (P ＜0.05).The toxic side effects of 3 ～4 such as neutrophil,hemoglobin,platelet,peripheral neurotoxicity,nausea and vomiting,diarrhea incidence were significantly lower in observation group than in the control group (P＜0.05) [30.3％(10/33) vs 3.0％ (1/33),27.3％ (9/33) vs 0.0％,21.2％ (7/33)vs 0.0％,24.2％ (8/33) vs 0.0％,24.2％ (12/33) vs 0.0％,21.2％ (7/33) vs 0.0％] ; there were no significant differences between two groups regarding hand foot syndrome and oral mucositis (P ＞ 0.05).Conclusion Oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer has a high efficacy.%目的 探讨奥沙利铂联合卡培他滨治疗晚期胃癌的临床价值.方法 将西安医学院附属医院66例晚期胃癌患者按随机数字表法分为观察组和对照组,每组33例.观察组患者给予奥沙利铂130 mg/m2静脉滴注,口服卡培他滨2 500 mg/(m2·d).对照组患者给予顺铂20 mg/m2静脉滴注,口服亚叶酸钙200 mg/m2;微量泵输入氟尿嘧啶2 400 mg/m2,共46 h.治疗2个周期后观察2组患者的临床疗效、生存质量及药物不良反应.结果 观察组总有效率为54.5％(18/33),明显高于对照组的33.3％(11/33),差异有统计学意义(P＜0.05).2组治疗后生活质量评分均明显高于治疗前[观察组:(88±8)分比(65±7)分;对照组:(79±9)分比(66±7)分],差异有统计学意义(P＜0.05).观察组治疗后的生活质量与对照组比较,差异有统计学意义(P＜0.05).观察组的中性粒细胞减少、血红蛋白降低、血小板减少、外周神经毒性、恶心呕吐、腹泻等Ⅲ～Ⅳ级不良反应发生率明显低于对照组,差异有统计学意义[30.3％(10/33)比3.0％(1/33)、27.3％(9/33)比0.0％、21.2％(7/33)比0.0％、24.2％ (8/33)比0.0％、24.2％(12/33)比0.0％、21.2％(7/33)比0.0％](P＜0.05).2组手足综合征、口腔黏膜炎Ⅲ～Ⅳ级不良反应发生率比较,差异无统计学意义(P＞0.05).结论 奥沙利铂联合卡培他滨能有效地治疗晚期胃癌,且能提高患者的生活质量.
展开▼
